America must invest at least $15 billion over the next five years to support its domestic biotechnology sector if it doesn’t want to lose to China, warns a national security commission made up ...

SINGAPORE: A 10-year-old girl died on Tuesday (Apr 8) after a fire broke out at a shophouse at River Valley Road where education and enrichment classes for children are conducted. Home Affairs ...

Analysts' ratings for Legend Biotech LEGN over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind ...

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition. WASHINGTON, April 8, 2025 /PRNewswire/ -- Today, the National Security ...

and a wonderful example of the power of biotechnology to protect species, both extant and extinct.” Drew Weisholtz is a reporter for TODAY Digital, focusing on pop culture, nostalgia and ...

Microsoft, a global giant, is celebrating its 50th anniversary with a range of exciting perks as well as new wallpapers. These wallpapers are specifically curated for Microsoft fans. If you’re also ...

Aurion Biotech has pushed out its CEO. Swiss healthcare company Alcon last week acquired a majority interest in Aurion, a clinical-stage startup in Seattle that is developing advanced cell ...

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon expected to pull back from the biotech industry, representing a blow to a ...

After struggling through a rough patch, the biotech industry seems to be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene ...

Evaxion Biotech AS (NASDAQ:EVAX) entered into a transformational partnership with MSD in September 2024, which is tracking well towards potential option exercise in the second half of 2025.

US healthcare giant Johnson & Johnson’s (NYSE: JNJ) venture capital arm has made its first investment in South Korea, leading a $20 million series B financing round for Prazer Therapeutics, a biotech ...